Close Menu

codevelopment agreement

The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.

The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.